NASDAQ:CLSNCelsion Stock Price, Forecast & News

$3.03

+0.68 (+28.94 %)

(As of 05/25/2020 03:32 PM ET)

Add

Compare

Today's Range

$2.41

Now: $3.03▼

$3.28

50-Day Range

$0.89

MA: $1.19▼

$2.35

52-Week Range

$0.69

Now: $3.03▼

$3.28

Volume22.56 million shs

Average Volume1.88 million shs

Market Capitalization$88.66 million

P/E RatioN/A

Dividend YieldN/A

Beta2.01

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Celsion.

2.8 Community Rank

Outperform Votes
Celsion has received 378 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Celsion has received 300 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Celsion has received 55.75% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote “Outperform” if you believe CLSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Celsion does not currently pay a dividend.
Dividend Growth
Celsion does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celsion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.30% of the stock of Celsion is held by insiders.
Percentage Held by Institutions
Only 8.46% of the stock of Celsion is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Celsion are expected to grow in the coming year, from ($0.56) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celsion is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celsion is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celsion has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.29 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CLSN

Previous Symbol

CUSIPN/A

CIK749647

Webwww.celsion.com

Phone609-896-9100

Debt

Debt-to-Equity Ratio0.53

Current Ratio2.54

Quick Ratio2.54

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00

Price / Sales177.32

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.63 per share

Price / Book4.81

Profitability

EPS (Most Recent Fiscal Year)($0.91)

Net Income$-16,850,000.00

Net Margins-3,908.00%

Return on Equity-120.14%

Return on Assets-48.44%

Miscellaneous

Employees29

Outstanding Shares29,260,000

Market Cap$88.66 million

Next Earnings Date8/12/2020 (Estimated)

OptionableOptionable

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

Celsion (NASDAQ:CLSN) Frequently Asked Questions

How has Celsion's stock been impacted by COVID-19 (Coronavirus)?

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLSN stock has increased by 206.1% and is now trading at $3.03. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Celsion?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celsion.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Celsion.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings data on Thursday, March, 26th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.10. The biotechnology company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 3,908.00% and a negative return on equity of 120.14%. View Celsion's earnings history.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Has Celsion been receiving favorable news coverage?

News stories about CLSN stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Celsion earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCelsion.

Who are some of Celsion's key competitors?

Some companies that are related to Celsion include Organogenesis (ORGO), Selecta Biosciences (SELB), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Avadel Pharmaceuticals (AVDL), Ovid Therapeutics (OVID), MannKind (MNKD), Rigel Pharmaceuticals (RIGL), Menlo Therapeutics (MNLO), Verastem (VSTM), Concert Pharmaceuticals (CNCE), Avid Bioservices (CDMO), Lannett (LCI), Neptune Wellness Solutions (NEPT) and OrganiGram (OGI). View all competitors.

What other stocks do shareholders of Celsion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and Novavax (NVAX).

Who are Celsion's key executives?

Celsion's management team includes the following people:

Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)
Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)
Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)
Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)
Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61)

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Who are Celsion's major shareholders?

Celsion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Eudaimonia Partners LLC (0.29%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View institutional ownership trends for Celsion.

Which major investors are buying Celsion stock?

CLSN stock was bought by a variety of institutional investors in the last quarter, including Eudaimonia Partners LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno, and Robert W Hooper. View insider buying and selling activity for Celsion.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $3.03.

How big of a company is Celsion?

Celsion has a market capitalization of $88.66 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff